CSL Behring
ProfileJobs

CSL Behring

Suggest Edit
    • Healthpharma
    CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
    Type
    Private
    HQ
    King of Prussia, US
    Founded
    1901
    Size (employees)
    4,945 (est)+3%
    Website
    cslbehring.com
    CSL Behring was founded in 1901 and is headquartered in King of Prussia, US
    Report incorrect company information

    Key People/Management at CSL Behring

    Paul Perreault

    Paul Perreault

    Chief Executive Officer and Managing Director
    David Lamont

    David Lamont

    CFO
    Gordon Naylor

    Gordon Naylor

    President, Seqirus
    Val Romberg

    Val Romberg

    Executive Vice President Manufacturing Operations and Planning
    Andrew Cuthbertson

    Andrew Cuthbertson

    Chief Scientific Officer and R&D Director
    Bill Campbell

    Bill Campbell

    Executive Vice President and Chief Commercial Officer
    Show more

    CSL Behring Office Locations

    CSL Behring has an office in King of Prussia
    King of Prussia, US (HQ)
    1020 1st Ave
    Show all (1)
    Report incorrect company information

    CSL Behring Financials and Metrics

    Summary Metrics

    Founding Date

    		1901
    Show all financial metrics
    Report incorrect company information

    Competitors

    STERIS
    Health - Public
    BioScrip
    Health - Public
    Cytokinetics
    Health - Public
    Perrigo
    Health - Public
    Compare competitors

    CSL Behring Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    CSL Behring News and Updates

    August 29, 2017

    CSL Behring to buy VC-backed Calimmune

    CSL Behring has agreed to acquire Calimmune Inc, a gene therapy company, for an upfront payment of $91 million. Calimmune's backers included Alexandria Venture Investments, RA Capital Healthcare Fund LP and Translational Accelerator LLC.
    Report incorrect company information
    Download PDF